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We found that non-small cell lung cancer (NSCLC) is remarkably sensitive to the regulation of glutamine
supply by testing the metabolic dependency of 11 cancer cell lines against regulation of glycolysis,
autophagy, fatty acid synthesis, and glutamine supply. Glutamine is known as a key supplement of cancer
cell growth that is converted to a-ketoglutarate for anabolic biogenesis via glutamate by glutaminase 1
(GLS1). GLS1 inhibition using 10 mM of bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulﬁde
(BPTES) showed about 50% cell growth arrest by SRB assay. By testing the synergistic effects of con-
ventional therapeutics, BPTES combined with 5-ﬂuorouracil (5-FU), an irreversible inhibitor of thymi-
dylate synthase, signiﬁcant effects were observed on cell growth arrest in NSCLC. We found that GLS1
inhibition using BPTES reduced metabolic intermediates including thymidine and carbamoyl phosphate.
Reduction of thymidine and carbamoyl-phosphate synthesis by BPTES treatment exacerbated pyrimidine
supply by combination with 5-FU, which induced cell death synergistically in NSCLC.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tyrosine kinase inhibitors for targeted therapy against lung
cancer showed a therapeutic limit of progression in overall survival
[1]. Themajor reason for this limit in targeted therapy appears to be
based on over half a million somatic mutations for cancer pro-
gression [2]. In the last decade, a growing number of reports have
initiated a discussion about the beneﬁts of metabolic regulation in
cancers (see reviews in Refs. [3,4]). Therefore, understanding the
metabolic character of non-small-cell lung cancer cell (NSCLC) may
provide a chance to improve therapeutic approaches to drug
resistance.
In this study, we tested the metabolic dependency of a cancer
cell panel composed of 11 different cancer cell lines, namely
NSCLC, renal, breast, stomach, liver, prostate, colon, ovarian, CNS,
leukemia, and melanoma, for four types of metabolic pathways,
including glycolytic inhibition using 2-deoxyglucose (see review
in Ref. [5]), autophagy inhibition using chloroquine (see review inGLS1, glutaminase 1, kidney-
do-1,3,4-thiadiazol-2-yl)ethyl
hetase.
gu, Goyang-si, Gyeonggi-do
).
Inc. This is an open access article uRef. [6]), fatty acid oxidation inhibition using etomoxir (an irre-
versible inhibitor of carnitine palmitoyltransferase-1, see review
in Ref. [7]), and glutaminolysis inhibition using glutamine-
depleted media or bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-
yl)ethyl sulﬁde (BPTES) [8,9]. NSCLC showed more dependency
on glutamine supply than other cancers (Fig. 1). In glutaminolysis,
the ﬁrst metabolic reaction is converting glutamine to glutamate
by glutaminase for the anaplerotic reaction in cancer [10].
Glutamine is considered to support cancer cell anabolism building
TCA intermediates through conversion to a-ketoglutarate (a-KG)
[11]. Recently, glutamine metabolism regulated by cancer-speciﬁc
glutaminase (EC 3.5.1.2, glutaminase 1, L-glutaminase, and gluta-
mine aminohydrolase) has been gaining attention in cancer
biology as it has been reported that high levels of kidney-type
glutaminase (glutaminase 1, GLS1, KGA) are associated with
oncogenic activation [12e14]. Furthermore, diminishing tumori-
genesis by GLS1 knockdown or inhibition using small molecules
was demonstrated in a hepatocellular carcinoma xenograft model
[15]. Here we explored the best combination of anti-cancer ther-
apeutics with GLS1 inhibition using BPTES and the related
mechanism in NSCLC.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Glutamine Metabolism is Critical for NSCLC Proliferation. Eleven types of cancer cells, including NSCLC, ovarian, CNS, hematopoietic, colon, renal, melanoma, breast, prostate,
stomach, and liver, were treated with (A) 2-deoxy-D-glucose (2-DG, 5 mM), (B) chloroquine (100 mM), (C) etomoxir (100 mM), and (D) glutamine-free medium for 48 h, and cell
proliferation was tested by the SRB assay. (E) Survival of NSCLC cells by BPTES treatment was tested by the SRB assay in various concentrations (0.1 nMe10 mM). (F) Clonogenic assay
was performed using A549 and EKVX cells with siRNAs of control and GLS1 (20 nM) for 2 weeks. (G) A549 and EKVX cells stably transduced with a control shRNA or GLS1 shRNA
were cultured, and stained with crystal violet after 2 weeks. p-Values were determined using two-tailed Student’s t-tests (ns, not signiﬁcant;+0.01 < p < 0.05;++0.001 < p < 0.01;
+++p < 0.001). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 3. Cell growth arrest is induced by combined BPTES and 5-FU treatment. NSCLC cells were treated with 10 mM of BPTES, 10 mM of 5-FU, or a combination of 10 mM of BPTES and
10 mM of 5-FU for 48 h. (A) The inhibitory effect of 5-FU on NSCLC proliferation was measured by the SRB assay after cells were treated with serial concentrations of BPTES for 48 h
(B) NSCLC survival is remarkably reduced by combined BPTES and 5-FU treatment. Cell proliferation was measured by the SRB assay after cells were treated with 10 mM of BPTES
alone, 10 mM of 5-FU alone, or a combination of the two for 48 h in NSCLC cell lines. p-Values were determined using two-tailed Student’s t-tests (ns, not signiﬁcant;
+0.01 < p < 0.05; ++0.001 < p < 0.01; +++p < 0.001).
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2.1. Cell culture and cells with stable knock down of GLS1
All cell lines were obtained from the US National Cancer Insti-
tute (MTA 1-2702-09). All cells were incubated at 37 C and
maintained at 5% CO2. IMR90 was obtained from ATCC and was
grown in DMED medium (Hyclone, Logan, UT, USA). Cells were
grown in RPMI 1640 medium (Hyclone) plus 10% fetal bovine
serum (FBS; Hyclone, Logan, UT, USA), penicillin, and streptomycin.
GLS1 shRNA vectors were obtained from sigma-aldrich. The se-
quences and RNAi Consortium clone IDs for each shRNA are as
follows. shGLS #1: GCA CAG ACA TGG TTG GTA TAT
(TRCN0000051135), shGLS #2: GCC CTG AAG CAG TTC GAA ATA
(TRCN0000051136). A549 and EKVX cells were transfected with
shRNA of GLS1 and two clones of each selected with puromycin for
further study.2.2. SRB assay
SRB was performed as previously described [16]. Cells (100 ml)
were inoculated into 96-well microtiter plates at plating densitiesFig. 2. NSCLC survival is reduced by a combination of GLS1 knockdown and 5-FU treatment.
of BPTES alone, 10 mM of 5-FU alone, or combined BPTES and 5-FU for 48 h in A549 and EKV
SRB assay was performed using 100 mM of carboplatin in A549 and EKVX. (D) Cell death was
p-Values were determined using two-tailed Student’s t-tests (ns, not signiﬁcant; +0.01 < pranging from 5000 to 20,000 cells/well depending on the doubling
time of the individual cell line. After cell inoculation, the microtiter
plates were incubated for 24 h prior to the addition of the experi-
mental drugs. The drugs were prepared at the appropriate con-
centrations (1010e104 M) and 100 ml was added to each well; the
plates were then incubated in CO2 incubator. The assay was
terminated by the addition of cold TCA. The cells were ﬁxed in situ
by gently adding 50 ml of cold 50% (w/v) TCA (ﬁnal concentration,
10% TCA) and incubated for 60 min at 4 C. The supernatant was
discarded, and the plates were washed ﬁve times with tap water
and then air dried. Sulforhodamine B solution (100 ml) at 0.4% (w/v)
in 1% acetic acid was added to each well, and the plates were then
left for 10 min at room temperature. After staining, the unbound
dye was removed by washing ﬁve times with 1% acetic acid; the
plates were then air dried. The bound stain was subsequently sol-
ubilized with 10 mM trizma base, and the absorbance was recorded
using an automated plate reader at a 515 nm.2.3. Western blot
Western blots were performed as previously described [17].
Brieﬂy, the cells were harvested, washed in phosphate-buffered(A) Cell proliferation was measured by the SRB assay after cells were treated with 10 mM
X. (B) The SRB assay was performed using 1 mM of geﬁtinib in A549 and EKVX. (C) The
measured with FACS in IMR90 as a normal control using the same treatment as above.
< 0.05; ++0.001 < p < 0.01; +++p < 0.001).
Fig. 4. Dual treatment with BPTES and 5-FU induced cell death through impairment of pyrimidine synthesis. (A) Thymidine levels were measured by LC-MS/MS after treatment
with 10 mM of BPTES, 10 mM of 5-FU, a combination of the two, or siRNA of GLS1 for 48 h in A549 and EKVX. (B) Carbamoyl phosphate levels were measured by LC-MS/MS after
treatment with 10 mM of BPTES, 10 mM of 5-FU, a combination of the two, or siRNA of GLS1 for 48 h in A549 and EKVX. (C) Immunoblotting of PARP and g-H2AX were performed in
A549 and EKVX after treatment of 10 mM of BPTES, 10 mM of 5-FU, or a combination for 48 h (D). Immunoblotting of PARP and g-H2AX were performed in A549 and EKVX after
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Fig. 4. (continued).
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150 mM NaCl, 1% (v/v) Triton X-100, 1 mM EDTA, and protease
inhibitors]. The lysates were analyzed using western blot.
2.4. Clonogenic assay
Cells were plated in 60 mm plates at 1000 cells per well in 3 ml
media. Media was not changed throughout the course of the
experiment. After 14 days, colonies were stained with 0.005%
crystal violet staining solution.
2.5. FITC annexin V apoptosis detection
The cells were incubated with or without 10 mMBPTES,10 mM5-
FU, or both for 48 h. The cells were then collected, washedwith cold
PBS, centrifuged at 1400 rpm for 3 min, and resuspended in 1
binding buffer at concentration of 1  106 cells/ml. 100 ml of the
solution was transferred to a 5-ml culture tube (1  105 cells), and10 mM of 5-FU treatment for 48 h following to 40 nM of CPSII siRNA treatment for 24 h. (E) Im
BPTES, 5-FU and siCPSII under the same conditions as above. (F) The effect of carbamoyl ph
together with or without 10 mM of BPTES for 48 h (G) A schematic diagram of possible syne
cancer cell growth. The role of GLS1 remains to be elucidated. p-Values were deter
++0.001 < p < 0.01; +++p < 0.001).5 ml each of annexin V-FITC and PI were added. The cells were
gently vortexed and incubated for 15 min at room temperature in
the dark. Then, 400 ml of 1 binding buffer was added to each tube,
and the samples were analyzed by FACS ﬂow cytometry (BD
Falcon).2.6. Quantitative measurement of carbamoyl phosphate and
thymidine
Standard metabolites and 13C5 glutamine were purchased from
Sigma-Aldrich (St. Louis, MO, USA). U-13C10, U-15C2 Thymidine was
obtained from Cambridge Isotope Laboratories (Tewksbury, MA,
USA). The cell number was ~1 million, and cells were harvested
using 1.4 mL of cold methanol/H2O (80/20, v/v) after sequential
washing with PBS and H2O. Then, the cells were lysed by vigorous
vortexing with 80% methanol, and 100 ml of the internal standard
solution was added. The internal standard solution consisted of
100 nM U-13C10, U-15C2 thymidine for thymidine and 5 mM 13C5munoblotting of CPSII, PARP and g-H2AX were performed in IMR-90 after treatment of
osphate on survival was measured by treatment with 100 mM of carbamoyl phosphate
rgistic inhibition of BPTES and 5-FU is suggested, which blocks pyrimidine synthesis in
mined using two-tailed Student’s t-tests (ns, not signiﬁcant; +0.01 < p < 0.05;
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extracted from the aqueous phase by liquideliquid extraction after
adding water and chloroform. The aqueous phase was dried using a
vacuum centrifuge and was reconstituted with 50 ml of 50%
methanol or acetonitrile prior to LCeMS/MS analysis.
For carbamoyl phosphate and thymidine, calibration curves
were generated using authentic standards, and the calibration
range was 1e10,000 nM (r2 > 0.99). The quantitation results were
normalized to the amount of protein in each sample. For thymidine
analysis, a HILIC column (HILIC plus 3.5 mm,100  2.1 mm; Agilent)
was used.
2.7. Statistical analysis
Statistical analysis was performed using Student’s t-test as
appropriate.
3. Result
3.1. NSCLC cell lines are selectively sensitive to glutamine depletion
We tested the metabolic dependency of a cancer cell panel
composed of 11 different cancer cell lines under normal nutrition
media and normoxia, namely NSCLC (A549), renal (SN12C), breast
(MCF7), stomach (SNU16), liver (Huh7), prostate (PC3), colon
(HT29), ovarian (OVCAR4), CNS (SNB19), leukemia (RPMI8226), and
melanoma (UACC257), for four types of metabolic pathways,
including glycolytic inhibition using 2-deoxyglucose (2-DG), auto-
phagy inhibition using chloroquine, fatty acid oxidation inhibition
using etomoxir (an irreversible inhibitor of carnitine
palmitoyltransferase-1), and glutaminolysis inhibition using
glutamine-depleted media (Fig. 1). Leukemia showed selective
dependency on glucose metabolism compared to other cancers
(Fig. 1A), and melanoma showed selective sensitivity on autophagy
inhibition (Fig. 1B). Single treatment of etomoxir did not show se-
lective dependency among cancers (Fig. 1C). Especially A549 hu-
man lung adenocarcinoma cell line showed selective glutamine
dependency for growth compared to the other cancer cells among
themetabolic challenges (Fig.1D).We testedwhether NSCLC shows
a common dependency on glutamine depletion or GLS1 inhibition
using BPTES. Interestingly, eight different NSCLC cell lines regard-
less of oncogenic differences showed universal dependency on
glutamine as well as GLS1 inhibition using BPTES (Fig. 1E). We
tested whether GLS1 knock down induce growth arrest in colony
formation assay using NSCLC cell lines such as A549 and EKVX
(Fig.1F). GLS1 knock down using siRNA of GLS1 resulted in over 50%
growth arrest of colony formation in NSCLC (Fig. 1F). To verify the
clonogenic assay using stable knockdown of GLS1, we have devel-
oped GLS1 stable knock down cell lines of A549 and EKVX using
shRNA of GLS1 (Fig. 1G). Two sub-clones were selected in each cell
line of A549 and EKVX, and GLS1 knock down was conﬁrmed by
immune-blotting. Clonogenic assay with GLS1 stable knock down
resulted in over 50% growth arrest of colony formation in A549 and
EKVX, which concurred with results from siRNA treatment of GLS1
(Fig. 1F).
3.2. GLS1 inhibition using BPTES combined with 5-FU potentiates
cell growth arrest
It is clear that single inhibition of GLS1 reduces cancer cell
growth but does not exhibit an adequate anti-cancer effect.
Therefore, we explored whether BPTES has a sensitizing effect
when combined with conventional lung cancer therapeutics, such
as 5-ﬂuorouracil (5-FU) as an irreversible inhibitor of thymidylate
synthetase (TYMS) [18] (Fig. 2A), geﬁtinib as an EGFR inhibitor (seereview [19]) (Fig. 2B), and carboplatin as a platinum-based anti-
neoplastic agent (see review [20]) (Fig. 2C). Interestingly, 10 mM of
BPTES showed a clear synergistic anti-cancer effect with 10 mM of
5-FU in A549 and EKVX cell lines among the three therapeutics
(Fig. 2A). In comparisonwith the NSCLC cancer cell lines, the IMR90
normal immortalized cell line did not show any cell growth arrest
or cell death induction (Fig. 2D). This suggests that BPTES treatment
combined with 5-FU affects more efﬁciently on fast growing cancer
cells such as NSCLC than on slow growing normal cells.
3.3. Combination treatment of BPTES and 5-FU signiﬁcantly induces
growth arrest with thymidine reduction in NSCLC
In Fig. 1E, eight different NSCLC cell lines showed signiﬁcant
dependency on GLS1 inhibition using BPTES. Although single
treatment with either BPTES (Fig. 1A) or 5-FU (Fig. 3A) resulted in
the reduction of cell growth in NSCLC, it is not sufﬁcient to induce
signiﬁcant cell death. Here, a dual treatment with 5-FU and BPTES
resulted in a growth reduction response not only in EKVX and A549
but also in most of the NSCLC cell lines, including NCI-H23, NCI-
H522, NCI-H226, HOP62, NCI-H322M and NCI-H460, in a syner-
gistic manner (Fig. 3B).
We tested whether GLS1 inhibition regulates pyrimidine syn-
thesis because BPTES showed synergistic effect with pyrimidine
synthesis inhibition of 5-FU. We analyzed changes in level of
thymidine after BPTES treatment or GLS1 knock down in A549 and
EKVX (Fig. 4A).We found that BPTES effectively reduced the level of
thymidine as well as synergistically reduced the thymidine level
with 5-FU treatment (Fig. 4A). Dual BPTES and 5-FU treatment
reduced the thymidine levels to approximately 20%e30% compared
with those in the control cells (Fig. 4A). As in Fig. 1F, GLS1 knock
down using speciﬁc siRNA also reduced the thymidine levels to
approximately 20% compared to the control in A549 and EKVX
(Fig. 4A). In the A549 and EKVX cell lines, BPTES treatment reduced
the levels of carbamoyl phosphate by 18% and 15%, whereas dual
BPTES and 5-FU treatment synergistically reduced these levels by
55% and 52% compared with 5-FU treatment (Fig. 4B). GLS1 knock
down using speciﬁc siRNA also reduced the level of carbamoyl
phosphate to approximately 20% compared to the control in A549
and EKVX (Fig. 4B). Carbamoyl phosphate synthetase II (CPSII) is an
enzyme that catalyzes reactions that produce carbamoyl phosphate
in the cytosol and serves as the rate-limiting enzyme in pyrimidine
synthesis [21]. To test whether GLS1 affects the level of carbamoyl
phosphate as a precursor of orotate that converts to dTMP through
dUMP, carbamoyl phosphate level was measured after BPTES
treatment (Fig. 4B). Data revealed that BPTES reduced the level of
carbamoyl phosphate as well as synergistically reduced the level
combined with 5-FU treatment (Fig. 4B). 5-FU reduces thymidine
synthesis through inhibiting thymidylate synthetase (TYMS). Car-
bamoyl phosphate synthesis is a precursor of dUMP as TYMS sub-
strate. Therefore decrease of carbamoyl phosphate production by 5-
FU treatment may be associated with cell death (Fig. 4C). Immu-
noblotting of poly ADP ribose polymerase (PARP) and g-H2AX
demonstrated that combined BPTES and 5-FU treatment increased
the levels of cleaved PARP and g-H2AX (Fig. 4C). This suggests that
the dual treatment is associated with cell death through DNA
damage. To test whether CPSII contributes to survival of NSCLC, the
CPSII knock down was tested with or without 5-FU in NSCLC
(Fig. 4D). Immunoblotting of PARP and g-H2AX demonstrated that
CPSII knock down combined with 5-FU treatment increased the
levels of cleaved PARP and g-H2AX (Fig. 4D). This suggests that
CPSII is critical in NSCLC survival. In order to compare the effect of
combination treatment or CPSII knock down on apoptosis in
normal immortalized cell line, IMR90 cells were employed (Fig. 4E).
Combination of BPTES and 5-FU or CPSII knock down combined
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H2AX in slow growing normal cell such as IMR90 (Fig. 4E). There-
fore blocking thymidine synthesis by combination of BPTES and 5-
FU appears to be effective on growth arrest of fast growing cancer.
To test whether GLS1 inhibition is signiﬁcant in growth arrest
through carbamoyl phosphate synthesis, cell growth and survival
was assayed after 10 mM of BPTES was supplied to NSCLC cells
together with or without 100 mM of carbamoyl phosphate for 48 h
(Fig. 4F). Carbamoyl phosphate reversed the BPTES mediated
decrease of NSCLC survival from about 50% to 80% of survival
(Fig. 4F). This implies that BPTES plays an important role in car-
bamoyl phosphate synthesis in NSCLC. This suggests that BPTES
and 5-FU synergistically blocks thymidine synthesis (Fig. 4G).
4. Discussion
Conventional treatment for NSCLC is a combination of 2 chemo
drugs. A common ﬁrst line therapeutic against NSCLC is carboplatin
that interacts with DNA to interfere with DNA repair. Carboplatin is
now popular in clinical treatment due to reduced side effects
compared to the previous compound cisplatin [22,23]. The
advanced targeted drug in NSCLC is Geﬁtinib (Iressa), approved by
The US Food and Drug Administration for the primary treatment of
NSCLC which contains speciﬁc mutations in the EGFR gene [24].
However, although NSCLC is the most common type of lung cancer,
only about 10% of cases have EGFR gene mutations. Therefore, the
vast majority of lung cancer patients are waiting for speciﬁc tar-
geted drugs. Yet, elaborated sequencing of NSCLC tumors have
revealed that over half a million somatic mutations cannot be
grouped with common mutations. NSCLC patients are desperately
looking for common therapeutic targets as a result. GLS1 levels
increase substantially in NSCLC, and this increase is inversely
correlated with the overall survival rate in NSCLC (data not shown).
Here we found that GLS1 knockdown or inhibition using BPTES
induces cell death, which potentiates an anti-cancer effect when it
is combined with TYMS inhibition using 5-FU in NSCLC.
Blocking the glutamate supply with BPTES alone was not sufﬁ-
cient to induce critical cell death. However, dual BPTES and 5-FU
treatment demonstrated a great synergistic effect in cell death in-
duction. We propose that the synergistic mechanism of the dual
therapy against GLS1 and TYMS is connected with the inactivation
of CPSII. The activation of CPSII depends on ATP levels [25] and
requires two ATPs for the catalysis of carbonate to carbamoyl
phosphate. Therefore, GLS1 induced decrease of carbamoyl phos-
phate synthesis may be associated with ATP level connected with
glutamate metabolism. The upstream regulation of CPSII by GLS1
remains to be answered in the near future (Fig. 4G).
It is established theory that the increased levels of GLS1 can be
used in anaplerotic reactions in cancer [26,27]. The rapid turnover
of glutamate leads to the synthesis of nucleotides and amino acids
[26]. Some groups have demonstrated that MYC regulates meta-
bolic gene expression via glycolytic genes including lactate dehy-
drogenase A and glutaminolysis genes including GLS1 [28]. This
suggests that the oncogene activated glutaminolysis supports a
signiﬁcant proportion of the biosynthetic needs of the cells. How-
ever, MYC mutation or activation signiﬁcantly correlates neither
with the increase of GLS1 in NSCLC.
In summary, inactivation of CPSII through GLS1 inhibition may
synergize DNA damage with 5-FU that blocks pyrimidine synthesis
in proliferative cancer cells.
Acknowledgements
This work was supported by a research grant from the National
Cancer Center of Korea to SYK (NCC1410670). The authors have nocompeting ﬁnancial interests to declare.
References
[1] F.S. Farhat, W. Houhou, Targeted therapies in non-small cell lung carcinoma:
what have we achieved so far? Ther. Adv. Med. Oncol. 5 (2013) 249e270.
[2] N. McGranahan, C. Swanton, Biological and therapeutic impact of intratumor
heterogeneity in cancer evolution, Cancer Cell 27 (2015) 15e26.
[3] S.Y. Kim, Cancer metabolism: strategic diversion from targeting cancer drivers
to targeting cancer suppliers, Biomol. Ther. (Seoul) 23 (2015) 99e109.
[4] S.Y. Kim, Cancer metabolism: targeting cancer universality, Arch. Pharm. Res.
38 (2015) 299e301.
[5] D. Zhang, J. Li, F. Wang, J. Hu, S. Wang, Y. Sun, 2-Deoxy-D-glucose targeting of
glucose metabolism in cancer cells as a potential therapy, Cancer Lett. 355
(2014) 176e183.
[6] X. Sui, R. Chen, Z. Wang, Z. Huang, N. Kong, M. Zhang, W. Han, F. Lou, J. Yang,
Q. Zhang, X. Wang, C. He, H. Pan, Autophagy and chemotherapy resistance: a
promising therapeutic target for cancer treatment, Cell Death Dis. 4 (2013)
e838.
[7] E. Currie, A. Schulze, R. Zechner, T.C. Walther, R.V. Farese Jr., Cellular fatty acid
metabolism and cancer, Cell Metab. 18 (2013) 153e161.
[8] K. Shukla, D.V. Ferraris, A.G. Thomas, M. Stathis, B. Duvall, G. Delahanty, J. Alt,
R. Rais, C. Rojas, P. Gao, Y. Xiang, C.V. Dang, B.S. Slusher, T. Tsukamoto, Design,
synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-
thiadiazol-2-yl)ethyl sulﬁde 3 (BPTES) analogs as glutaminase inhibitors,
J. Med. Chem. 55 (2012) 10551e10563.
[9] Y. Zhao, E.B. Butler, M. Tan, Targeting cellular metabolism to improve cancer
therapeutics, Cell Death Dis. 4 (2013) e532.
[10] C.V. Dang, Glutaminolysis: supplying carbon or nitrogen or both for cancer
cells? Cell Cycle 9 (2010) 3884e3886.
[11] M.V. Ruiz-Perez, F. Sanchez-Jimenez, F.J. Alonso, J.A. Segura, J. Marquez,
M.A. Medina, Glutamine, glucose and other fuels for cancer, Curr. Pharm. Des.
20 (2014) 2557e2579.
[12] M.O. Yuneva, T.W. Fan, T.D. Allen, R.M. Higashi, D.V. Ferraris, T. Tsukamoto,
J.M. Mates, F.J. Alonso, C. Wang, Y. Seo, X. Chen, J.M. Bishop, The metabolic
proﬁle of tumors depends on both the responsible genetic lesion and tissue
type, Cell Metab. 15 (2012) 157e170.
[13] A. Le, A.N. Lane, M. Hamaker, S. Bose, A. Gouw, J. Barbi, T. Tsukamoto,
C.J. Rojas, B.S. Slusher, H. Zhang, L.J. Zimmerman, D.C. Liebler, R.J. Slebos,
P.K. Lorkiewicz, R.M. Higashi, T.W. Fan, C.V. Dang, Glucose-independent
glutamine metabolism via TCA cycling for proliferation and survival in B cells,
Cell Metab. 15 (2012) 110e121.
[14] P. Gao, I. Tchernyshyov, T.C. Chang, Y.S. Lee, K. Kita, T. Ochi, K.I. Zeller, A.M. De
Marzo, J.E. Van Eyk, J.T. Mendell, C.V. Dang, c-Myc suppression of miR-23a/b
enhances mitochondrial glutaminase expression and glutamine metabolism,
Nature 458 (2009) 762e765.
[15] Y. Xiang, Z.E. Stine, J. Xia, Y. Lu, R.S. O’Connor, B.J. Altman, A.L. Hsieh,
A.M. Gouw, A.G. Thomas, P. Gao, L. Sun, L. Song, B. Yan, B.S. Slusher, J. Zhuo,
L.L. Ooi, C.G. Lee, A. Mancuso, A.S. McCallion, A. Le, M.C. Milone, S. Rayport,
D.W. Felsher, C.V. Dang, Targeted inhibition of tumor-speciﬁc glutaminase
diminishes cell-autonomous tumorigenesis, J. Clin. Invest. 125 (2015)
2293e2306.
[16] S.H. Lee, N. Kim, S.J. Kim, J. Song, Y.D. Gong, S.Y. Kim, Anti-cancer effect of a
quinoxaline derivative GK13 as a transglutaminase 2 inhibitor, J. Cancer Res.
Clin. Oncol. 139 (2013) 1279e1294.
[17] B.M. Ku, D.S. Kim, K.H. Kim, B.C. Yoo, S.H. Kim, Y.D. Gong, S.Y. Kim, Trans-
glutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell
carcinoma, FASEB J. 27 (2013) 3487e3495.
[18] C. Heidelberger, N.K. Chaudhuri, P. Danneberg, D. Mooren, L. Griesbach,
R. Duschinsky, R.J. Schnitzer, E. Pleven, J. Scheiner, Fluorinated pyrimidines, a
new class of tumour-inhibitory compounds, Nature 179 (1957) 663e666.
[19] J. Minguet, K.H. Smith, P. Bramlage, Targeted therapies for treatment of non-
small cell lung cancer-recent advances and future perspectives, Int. J. Cancer
138 (2016) 2549e2561.
[20] A. Rossi, M. Di Maio, Platinum-based chemotherapy in advanced non-small-
cell lung cancer: optimal number of treatment cycles, Expert Rev. Anti-
cancer Ther. (2016) 1e8.
[21] S.M. Kalman, P.H. Dufﬁeld, T. Brzozowski, Puriﬁcation and properties of a
bacterial carbamyl phosphate synthetase, J. Biol. Chem. 241 (1966)
1871e1877.
[22] H. Okamoto, K. Watanabe, H. Kunikane, A. Yokoyama, S. Kudoh, T. Asakawa,
T. Shibata, H. Kunitoh, T. Tamura, N. Saijo, Randomised phase III trial of car-
boplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or
poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702,
Br. J. Cancer 97 (2007) 162e169.
[23] A. Schmittel, L. Fischer von Weikersthal, M. Sebastian, P. Martus, K. Schulze,
P. Hortig, M. Reeb, E. Thiel, U. Keilholz, A randomized phase II trial of irino-
tecan plus carboplatin versus etoposide plus carboplatin treatment in patients
with extended disease small-cell lung cancer, Ann. Oncol. 17 (2006) 663e667.
[24] E.S. Kim, V. Hirsh, T. Mok, M.A. Socinski, R. Gervais, Y.L. Wu, L.Y. Li,
C.L. Watkins, M.V. Sellers, E.S. Lowe, Y. Sun, M.L. Liao, K. Osterlind, M. Reck,
A.A. Armour, F.A. Shepherd, S.M. Lippman, J.Y. Douillard, Geﬁtinib versus
docetaxel in previously treated non-small-cell lung cancer (INTEREST): a
randomised phase III trial, Lancet 372 (2008) 1809e1818.
J.-S. Lee et al. / Biochemical and Biophysical Research Communications 477 (2016) 374e382382[25] S.M. Shaw, E.A. Carrey, Regulation of the mammalian carbamoyl-phosphate
synthetase II by effectors and phosphorylation. Altered afﬁnity for ATP and
magnesium ions measured using the ammonia-dependent part reaction, Eur.
J. Biochem. 207 (1992) 957e965.
[26] R.J. DeBerardinis, A. Mancuso, E. Daikhin, I. Nissim, M. Yudkoff, S. Wehrli,
C.B. Thompson, Beyond aerobic glycolysis: transformed cells can engage in
glutamine metabolism that exceeds the requirement for protein and nucle-
otide synthesis, Proc. Natl. Acad. Sci. 104 (2007) 19345e19350.[27] A. Le, A.N. Lane, M. Hamaker, S. Bose, A. Gouw, J. Barbi, T. Tsukamoto,
C.J. Rojas, B.S. Slusher, H. Zhang, Glucose-independent glutamine metabolism
via TCA cycling for proliferation and survival in B cells, Cell Metab. 15 (2012)
110e121.
[28] P. Gao, I. Tchernyshyov, T.-C. Chang, Y.-S. Lee, K. Kita, T. Ochi, K.I. Zeller,
A.M. De Marzo, J.E. Van Eyk, J.T. Mendell, c-Myc suppression of miR-23a/b
enhances mitochondrial glutaminase expression and glutamine metabolism,
Nature 458 (2009) 762e765.
